

Bio Farma and MSD signed a framework agreement related to technology transfer cooperation to produce the human papillomavirus (HPV) vaccine locally in Indonesia

JAKARTA, INDONESIA, December 13, 2022 Bio Farma, Holding SOE Pharmacy with subsidiaries Kimia Farma and Indofarma, today signed a framework agreement related to technology transfer cooperation with MSD (trade name Merck & Co., Inc., Rahway, NJ, USA), to produce locally the MSD 4-valent human papillomavirus (HPV) vaccine. The agreement was signed by George Stylianou, Managing Director of MSD Indonesia and Honesti Basyir, CEO of Bio Farma Induk Holding and witnessed by the Minister of Health of the Republic of Indonesia, Budi Gunadi Sadikin, Deputy Minister I of BUMN Pahala Nugraha Mansury, Representative of the US Embassy in Indonesia, and the President of MSD Asia Pacific, David Peacock.

Based on the MSD and Bio Farma partnership that has existed since 2016, today's announcement of a framework agreement for the local production of the HPV vaccine has the potential to increase the capability and capacity of domestic vaccine production in Indonesia. Based on this framework, the parties will continue to work together towards an agreement to support the manufacture of local HPV vaccines in Indonesia.

Currently the HPV vaccine has been used for the introduction of the HPV immunization program in various districts and cities and the HPV immunization program will continue to be expanded to become a national scale program in 2023.

(left-right) Deputy Minister I of BUMN Pahala Nugraha Mansury; MSD Asia Pacific President, David Peacock; Managing Director of MSD Indonesia, George Stylianou; CEO of Bio Farma Induk Holding, Honesti Basyir; and the Minister of Health of the Republic of Indonesia, Budi Gunadi Sadikin.



(left-right) Deputy Minister I of BUMN Pahala Nugraha Mansury; MSD Asia Pacific President, David Peacock; Managing Director of MSD Indonesia, George Stylianou; CEO of Bio Farma Induk Holding, Honesti Basyir; and the Minister of Health of the Republic of Indonesia, Budi Gunadi Sadikin.

Minister of Health of the Republic of Indonesia Budi Gunadi Sadikin said the collaboration between Bio Farma and MSD was a real form of collaboration between parties to support Health Transformation in Indonesia, especially in efforts to strengthen the promotive and preventive primary service pillars which is one of the Ministry of Health's priorities. I believe that the potential for transfer of technology in terms of expertise, knowledge and experience from MSD as a leading global manufacturer of HPV vaccines will be beneficial for Bio Farma and for the independence of the Health Sector in Indonesia, especially in vaccine development.

In line with the comments from the Minister of Health, Deputy Minister I of the State-Owned Enterprises of the Republic of Indonesia Pahala Nugraha Mansury stated, We hope that the collaboration between MSD and Bio Farma will be an important step regarding domestic vaccine production in Indonesia.

Bio Farma Director Honesti Basyir added, "The signing of the Bio Farma & MSD agreement is a major milestone for Bio Farma. It's time for us to prove our commitment, increase the capacity of a larger product. This is an extraordinary opportunity for Bio Farma because it is in line with its vision, namely to become a global company. Apart from that, Bio Farma already has hundreds of years of experience in the vaccine field and now is the time for us to build a new milestone with MSD. For me acceleration is very important. Thanks to MSD for choosing Bio Farma as a partner.

"MSD will continue to expand production and availability of our HPV vaccine d to meet the unprecedented levels of demand we are seeing globally. We are continuing to work towards our goal of reducing the incidence of cervical cancer worldwide through increasing access to HPV vaccination and implementing immunization programmes. new and expanded plan. At MSD we are proud to support the global strategy of the World Health Organization (WHO) to accelerate the elimination of cervical cancer as a public health problem" said David Peacock, President Asia Pacific, MSD.

The signing of the agreement today coincides with Nusantara Day, and brings the best vaccine manufacturing capabilities from Bio Farma and MSD to Indonesia.

About Bio Farma

PT Bio Farma (Persero) is the largest state-owned pharmaceutical holding company in Indonesia engaged in the health sector with end-to-end services, ranging from pharmaceutical research and development, manufacturing and distribution, to retail pharmacy operations, clinics and clinical laboratories. To support its business activities, Bio Farma has a head office and factory covering an area of 91,058 square meters in Bandung. The company also has a representative office in Jakarta. With a production capacity of more than 3.2 billion vaccine doses per year, the company has exported its products to more than 150 countries. Bio Farma is the holding company of three pharmaceutical issuers on the Indonesia Stock Exchange (IDX), namely PT Kimia Farma Tbk (KAEF), PT Indofarma Tbk (INAF). For more information, visit: www.biofarma.co.id

About MSD

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are united in our purpose: We use the power of advanced science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of essential medicines and vaccines.

We aspire to be the world's leading research-intensive biopharmaceutical company and today, we are at the forefront of research to provide innovative healthcare solutions that advance the prevention and treatment of disease in humans and animals. We foster a global workforce that is diverse and inclusive and operates responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on [Twitter](#), [LinkedIn](#) and [YouTube](#)

Media Contact:

R. Rifa Herdian
Corporate Seretary &
Investor Relations PT
Bio Farma (Persero)
+628125428844
rifaherdia@biofarma.co.id